HistoCyte – Lung Cancer controls
Gaining over 15,000 cases this 2024 and leading with the lowest survival rate for cancer types, lung cancer has been in the forefront of cancer cases in Australia. Biomarkers such ALK, ROS1, PD-L1, and BRAF are used in IHC and molecular laboratory techniques to identify specific types of lung cancer and guide targeted therapy.
Biocartis – Clinical utility of Idylla EGFR
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Within 150 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge
Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. A recent publication of a large prospective study1 demonstrates the Idylla™ EGFR Mutation Test leads to
New Study Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions
Products are for professional/laboratory use only. New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) This study shows that Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods:
New Study Shows Rapid EGFR testing with Idylla!
Products are for professional/laboratory use only. Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
ZytoVision FISH probe for ROS1 translocations
Products are for professional/laboratory use only. For patients with advanced lung cancer, the expected median survival is approximately one year however treatment with targeted tyrosine kinase inhibitor (TKI) therapy can improve outcomes for patients who have certain molecular alterations that can be identified by molecular testing1.